FourThought Financial’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

FourThought Financial’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$18K	Buy	297 +156	+111%	+$10.9K	﹤0.01%	894
2022 Q2	$11K	Hold	141	–	–	﹤0.01%	1014
2022 Q1	$15K	Buy	141 +10	+8%	+$975	﹤0.01%	976
2021 Q4	$14K	Sell	131 -171	-57%	-$18.7K	﹤0.01%	1019
2021 Q3	$33K	Sell	302 -8	-3%	-$831	﹤0.01%	821
2021 Q2	$29K	Sell	310 -8	-3%	-$736	﹤0.01%	859
2021 Q1	$29K	Sell	318 -94	-23%	-$7.93K	﹤0.01%	829
2020 Q4	$30K	Buy	+412	New	+$30.6K	﹤0.01%	789

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

FourThought Financial's HZNP Position: Q3 2022 in Review

FourThought Financial increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 111% in Q3 2022, buying an estimated $10.9K and bringing the position to 297 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #894.

FourThought Financial first reported a position in HZNP in Q4 2020 and has held it in 8 quarters since. The position peaked at $33K in Q3 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

FourThought Financial held 297 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $18K as of Q3 2022.
FourThought Financial bought 156 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $10.9K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #894 holding.
FourThought Financial first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $33K in Q3 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.